DadFinStart your free week
DadFin › Stocks › Real Estate › SBRA

Sabra Health Care REIT, Inc. (SBRA) stock score

Real Estate · REIT - Healthcare Facilities · United States

$18.96 ▲ +0.64% today

35.0
Dad Score, out of 100
weak

Sabra Health Care REIT, Inc. (SBRA) is a REIT - Healthcare Facilities company in the Real Estate sector, listed in the United States. On DadFin's weekly run it scores 35.0 out of 100 on the Dad Score, a weak reading that places the business ahead of 35% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Real Estate it ranks #163 of 240. Its strongest axes are growth, conviction and liquidity; its weakest are valuation and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Average
Growth
Above average
Price action
Below average
Risk
Average
Conviction
Above average
Liquidity
Above average
Macro
Strong

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)73.7×
P/E (forward)23.7×
Dividend yield6.25%
Return on capital5.2%
Operating margin-12.5%
Revenue growth (YoY)+10.1%
FCF yield4.7%
Net debt / EBITDA6.47×
Piotroski F-Score6 / 9
52-week change+13.7%
Market cap$4.9B
Next earningsNov 4, 2026

What subscribers see on SBRA

Start your free weekSubscriber? Open the full research →

REIT - Healthcare Facilities peers

StockCompanyDad ScoreBandMarket cap
WELLWelltower Inc.46.6middling$164.1B
VTRVentas, Inc.41.7middling$43.1B
OHIOmega Healthcare Investors, Inc.77.0good$14.4B
DOCHealthpeak Properties, Inc.37.7weak$13.8B
AHRAmerican Healthcare REIT, Inc.51.5middling$11.1B
CTRECareTrust REIT, Inc.29.1weak$8.6B
NHINational Health Investors, Inc.82.4good$3.2B
LTCLTC Properties, Inc.92.3strong$2.3B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.